In vivo engineering of CAR immune cells by nonviral nanoparticles

1. From concept to cure: the evolution of CAR-T cell therapy10.1016/j.ymthe.2025.03.005 ↗

2. The future of engineered immune cell therapies10.1126/science.abq6990 ↗

3. Beyond the blood: expanding CAR T cell therapy to solid tumors10.1038/s41587-024-02446-2 ↗

4. From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy10.1186/s12967-024-06052-3 ↗

5. Advancements and challenges in CAR T cell therapy in autoimmune diseases10.1038/s41584-024-01139-z ↗

6. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy10.1038/s41591-024-03084-6 ↗

7. The landscape of CAR-engineered innate immune cells for cancer immunotherapy10.1038/s43018-025-01015-z ↗

8. State of the art in CAR-based therapy: in vivo CAR production as a revolution in cell-based cancer treatment10.1007/s13402-025-01056-7 ↗

9. CAR immune cells: design principles, resistance and the next generation10.1038/s41586-023-05707-3 ↗

10. Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold10.3390/cells9051182 ↗

11. CAR T therapy beyond cancer: the evolution of a living drug10.1038/s41586-023-06243-w ↗

12. Mechanisms of action and limitations of monoclonal antibodies and single chain fragment variable (scFv) in the treatment of cancer10.3390/biomedicines11061610 ↗

13. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia10.1016/j.ccell.2022.04.001 ↗

14. The physical landscape of CAR-T synapse10.1016/j.bpj.2023.09.004 ↗

15. Discordant CAR-T cell signaling: implications of divergence from physiological T cell activation10.1186/s12967-025-06857-w ↗

16. In vivo CD19 CAR T-Cell therapy for refractory systemic lupus erythematosus10.1056/NEJMc2509522 ↗

17. Tracing the development of CAR-T cell design: from concept to next-generation platforms10.3389/fimmu.2025.1615212 ↗

18. Engineering resilient CAR T cells for immunosuppressive environment10.1016/j.ymthe.2025.01.035 ↗

19. Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits10.1016/j.celrep.2024.114145 ↗

20. Long-term outcomes following CAR T cell therapy: what we know so far10.1038/s41571-023-00754-1 ↗

21. Autologous, allogeneic, in vivo CAR for autoimmune diseases10.1016/j.tips.2025.11.001 ↗

22. Advancements in personalized CAR-T therapy: comprehensive overview of biomarkers and therapeutic targets in hematological malignancies10.3390/ijms25147743 ↗

23. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion10.1038/s41571-022-00607-3 ↗

24. CAR-T-Cell-Based cancer immunotherapies: potentials, limitations, and future prospects10.3390/jcm13113202 ↗

25. Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma10.1038/s41409-025-02539-9 ↗

26. In vivo CAR engineering for immunotherapy10.1038/s41577-025-01174-1 ↗

27. Synergistic integration of mRNA-LNP with CAR-engineered immune cells: pioneering progress in immunotherapy10.1016/j.ymthe.2024.09.019 ↗

28. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment10.1016/j.ebiom.2024.105266 ↗

29. In vivo chimeric antigen receptor (CAR)-T cell therapy

30. Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies

31. Infection complications after lymphodepletion and dosing of chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia or B cell non-hodgkin lymphoma10.3390/cancers13071684 ↗

32. Cytokine release syndrome10.1186/s40425-018-0343-9 ↗

33. How I treat refractory CRS and ICANS after CAR T-cell therapy

34. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours10.1038/s41571-022-00704-3 ↗

35. In Vivo CAR-T therapy for cancer treatment: mechanisms, technological advances, and clinical translation10.32604/or.2026.076420 ↗

36. Small-molecule control of CAR T cells10.1038/s41570-025-00768-6 ↗

37. Application and design of switches used in CAR10.3390/cells11121910 ↗

38. CAR T cell locomotion in solid tumor microenvironment10.3390/cells11121974 ↗

39. Direct in vivo CAR T cell engineering10.1016/j.tips.2024.03.004 ↗

40. Strategies for altering delivery technologies to optimize CAR therapy10.3390/ijms26073206 ↗

41. Improving CAR T-Cell persistence10.3390/ijms221910828 ↗

42. The past, present, and future of non-viral CAR T cells10.3389/fimmu.2022.867013 ↗

43. In vivo human T cell engineering with enveloped delivery vehicles10.1038/s41587-023-02085-z ↗

44. Accelerating and optimising CAR T-cell manufacture to deliver better patient products10.1016/S2352-3026(24)00273-4 ↗

45. Cost-effective strategies for CAR-T cell therapy manufacturing

46. In vivo CAR T cell generation to treat cancer and autoimmune disease10.1126/science.ads8473 ↗

47. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers10.1038/nnano.2017.57 ↗

48. In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma10.1186/s13046-024-03179-5 ↗

49. Revolutionizing cancer treatment: the emerging potential and potential challenges of in vivo self-processed CAR cell therapy10.7150/thno.101941 ↗

50. Targeted gene delivery systems for T-cell engineering10.1007/s13402-024-00954-6 ↗

51. Optimizing viral transduction in immune cell therapy manufacturing: key process design considerations10.1186/s12967-025-06524-0 ↗

52. Progress in pseudotyping lentiviral vectors towards cell-specific gene delivery In vivo10.3390/v17060802 ↗

53. In vivo generation of CAR T cells in the presence of human myeloid cells10.1016/j.omtm.2022.06.004 ↗

54. Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors

55. In vivo generated human CAR T cells eradicate tumor cells10.1080/2162402X.2019.1671761 ↗

56. In vivo generation of CAR T cells selectively in human CD4+ lymphocytes10.1016/j.ymthe.2020.05.005 ↗

57. Targeted In vivo generation of CAR T and NK cells utilizing an engineered lentiviral vector platform10.1182/blood-2023-189087 ↗

58. Antibodies to combat viral infections: development strategies and progress10.1038/s41573-022-00495-3 ↗

59. Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells10.1136/jitc-2021-002737 ↗

60. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering10.1136/jitc-2022-006292 ↗

61. A phase 1, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory CD19+ B-Cell malignancies10.1182/blood-2024-208461 ↗

62. Technologies for chimeric antigen receptor transgene delivery10.1016/j.molmed.2025.05.011 ↗

63. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma10.1016/S0140-6736(25)01030-X ↗

64. J.I. Andorko, R.M. Russell, B.C. Schnepp, D. Grubaugh, K.F. Mullen, A. Wakabayashi, L.J. Carrington, T. O'Malley, L. Kuri-Cervantes, T.D. Culp, P.R. Johnson, Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation, Mol. Ther. 33 4937-4952. https://doi.org/10.1016/j.ymthe.2025.06.036.10.1016/j.ymthe.2025.06.036 ↗

65. Genome integration of human DNA oncoviruses10.1128/jvi.00562-25 ↗

66. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy10.1038/s41591-024-02826-w ↗

67. Modulation of immune responses in lentiviral vector-mediated gene transfer10.1016/j.cellimm.2018.04.012 ↗

68. Precision medicine: in vivo CAR therapy as a showcase for receptor-targeted vector platforms10.1016/j.ymthe.2022.05.018 ↗

69. Viral and non-viral systems to deliver gene therapeutics to clinical targets10.3390/ijms25137333 ↗

70. CAR T cells produced in vivo to treat cardiac injury10.1126/science.abm0594 ↗

71. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism10.1002/smll.202304378 ↗

72. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles10.1136/jitc-2025-011759 ↗

73. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs10.1016/j.ymthe.2021.06.004 ↗

74. Recent advances in mRNA-LNP delivery systems for extrahepatic organs: a review10.1021/acs.molpharmaceut.5c00385 ↗

75. The impact of chemical reactivity on the quality and stability of RNA-LNP pharmaceuticals10.1038/s41570-025-00763-x ↗

76. Structural and componential design: new strategies regulating the behavior of lipid-based nanoparticles in vivo10.1039/D3BM00387F ↗

77. Lipid nanoparticles for nucleic acid delivery beyond the liver10.1089/hum.2024.106 ↗

78. Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies - challenges and opportunities10.1016/j.jconrel.2024.04.022 ↗

79. In vivo generation of CAR myeloid cells through erythrocyte-mediated mRNA delivery for cancer immunotherapy10.1126/scitranslmed.ady6730 ↗

80. Advances in engineering myeloid cells for cell therapy applications10.1021/acssynbio.4c00589 ↗

81. From bench to body: in vivo CAR engineering in the clinic

82. Applications of nanoparticles in CAR-T cell therapy: non-viral manufacturing, enhancing in vivo function, and in vivo generation of CAR-T cells10.1007/s12032-025-02928-6 ↗

83. Biodegradable targeted polymeric mRNA nanoparticles enable in vivo CD19 CAR T cell generation and lead to B cell depletion10.1126/sciadv.adz1722 ↗

84. CAR-neutrophils produced in vivo to treat glioma10.1038/s41551-026-01656-0 ↗

85. Leveraging T cell-specific fusogenicity of HIV for in vivo mRNA delivery to produce human CAR-T cells10.1016/j.celbio.2025.100011 ↗

86. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo10.1038/s41467-020-19486-2 ↗

87. Harnessing the loop: the perspective of circular RNA in modern therapeutics10.3390/vaccines13080821 ↗

88. Self-amplifying RNA (saRNA) and circular RNA (circRNA) vaccines: progress, evidence gaps, and translational pathways for durable and scalable immunization10.1080/21645515.2026.2661120 ↗

89. Nanoparticle-mediated gene therapy in women's health: progress, delivery challenges, and the need for sex, age, and ancestry informed design10.1021/acsbiomaterials.5c00445 ↗

90. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy10.1038/s41375-024-02444-y ↗

91. Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery10.1002/adhm.202001812 ↗

92. mRNA-based cancer therapeutics10.1038/s41568-023-00586-2 ↗

93. Tailor made: the art of therapeutic mRNA design10.1038/s41573-023-00827-x ↗

94. Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages10.1016/j.omtn.2022.01.004 ↗

95. Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies?10.3390/ijms21218305 ↗

96. High-throughput automation of endosomolytic polymers for mRNA delivery10.1021/acsabm.0c01463 ↗

97. pH-Dependent phase behavior and stability of cationic Lipid-mRNA nanoparticles10.1016/j.xphs.2021.11.004 ↗

98. Efficient mRNA delivery using lipid nanoparticles modified with fusogenic coiled-coil peptides10.1039/D3NR02175K ↗

99. Compact polyethylenimine-complexed mRNA vaccines10.1038/s41565-025-01961-w ↗

100. The platform technology approach to mRNA product development and regulation10.3390/vaccines12050528 ↗